Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

• Gilead Sciences, Inc. recently reported third-quarter revenue of $8.3 billion, which exceeded the consensus estimate of $7.81 billion, and the company raised its full-year product sales guidance, signaling strong commercial performance and demand for its therapies.
• The company announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar), demonstrating that the majority of participants with primary biliary cholangitis achieved the alkaline phosphatase normalization composite endpoint, which supports the drug's potential to become a key treatment in liver disease.
• Gilead Sciences, Inc. has raised its dividend for 11 consecutive years, maintaining a quarterly dividend of $0.82 per share, which provides a stable income stream and reflects management's confidence in the company's long-term cash flow generation from its HIV portfolio.
• Analyst sentiment has improved significantly, with UBS Group raising its price target to $195 and DZ Bank increasing its target to $191, while the overall consensus rating remains a Moderate Buy with an average price target of $170.15, suggesting the stock may still have room to grow relative to expert expectations.
• The stock is currently trading at $167.57, which is near its 52-week high of $176.58, indicating strong momentum and investor confidence in the company's recent earnings beats and pipeline advancements.